Agnese Cattaneo

Catch up on our virtual symposium. Paolo Ghia, Università Vita-Salute San Raffaele, Milano, IT, discussed clinical developments in BTK inhibitors to treat first-line #CLL.  Watch to learn about the current and future perspectives of BTK inhibitors in CLL 👉 https://loom.ly/PisoPD0 #lymphoma #lymsm

2

Bone-active drugs in pre-menopausal women with breast cancer under hormone deprivation therapies Authors Maria Francesca Birtolo, Rebecca Pedersini, Andrea Palermo, Walter Vena, Emanuela Morenghi, Giacomo Cristofolini, Barbara Presciuttini, Gaia Tabacco, Anda Mihaela Naciu, Stella Pigni, Marta Laganà, Federica Mazzoleni, Deborah C., Antea Ciafardini, Mauro Pagani, davide farina, Luca Balzarini, Alberto Zambelli, Rosalba Torrisi, Luisella Cianferotti, Nicola Napoli, Antonio Carlo Bossi, Andrea Gerardo Lania, Alfredo Berruti, Gherardo Mazziotti Abstract Background Bone health management in premenopausal women with breast cancer (BC) under hormone-deprivation therapies (HDTs) is often challenging, and the effectiveness of bone-active drugs is still unknown. Methods This retrospective multicenter study included 306 premenopausal women with early BC undergoing HDTs. Bone mineral density (BMD) and morphometric vertebral fractures (VFs) were assessed 12 months after HDT initiation and then after at least 24 months. Results After initial assessment, bone-active drugs were prescribed in 77.5% of women (151 denosumab 60 mg/6 months, 86 bisphosphonates). After 47.0 ± 20.1 months, new VFs were found in 16 women (5.2%). Vertebral fracture risk was significantly associated with obesity (odds ratio [OR] 3.87, P = .028), family history of hip fractures or VFs (OR 3.21, P = .040], chemotherapy-induced menopause (OR 6.48, P < .001), preexisting VFs (OR 25.36, P < .001), baseline T-score less than or equal to −2.5 standard deviation (SD) at any skeletal site (OR 4.14, P = .036), and changes at lumbar and total hip BMD (OR 0.94, P = .038 and OR 0.88, P < .001, respectively). New VFs occurred more frequently in women untreated compared to those treated with bone-active drugs (14/69, 20.8% vs 2/237, 0.8%; P < .001) and the anti-fracture effectiveness remained significant after correction for BMI (OR 0.03; P < .001), family history of fractures (OR 0.03; P < .001), chemotherapy-induced menopause (OR 0.04; P < .001), and preexisting VFs (OR 0.01; P < .001). Conclusions Premenopausal women under HDTs are at high risk of VFs in relationship with high BMI, densitometric diagnosis of osteoporosis, preexisting VFs, and family history of osteoporotic fractures. Vertebral fractures in this setting might be effectively prevented by bisphosphonates or denosumab. EJE Volume 191, Issue 2, August 2024 Read the full article 👉 https://lnkd.in/dHy9v263 ESE Member Access free via 👉 https://lnkd.in/ep48a8bR #breastcancer #premenopausal

11

📌 Giacomo Lazzaro about the impact of the #europeancancersummit , the most pressing issue in oncology and his opinion of #OncoDaily European Cancer Organisation World Health Organization #Cancer #GlobalOncology #Healthcare #MedNews #Health #Medicine #OncoDaily #Oncology

18

We are happy to present a brand-new DIGI-MEd publication focused on the digitisation process in medicines’ clinical trials from a new European regulations’ perspective.​ ​ IRCCS San Raffaele Hospital's Head of Clinical Research and Development and pharmacologist Professor Carlo Tomino discusses the recent improvements of #EuropeanRegulation on Interventional Drug Clinical Trials (Reg 536/2014) marking a transformative moment for Companies, Healthcare Facilities and Ethics Committees.​ ​ Professor Tomino analyses the European Union's aim to improve the competitiveness of its clinical research processes by aligning them with global regulatory standards and ensuring high level standards of safety and transparency such as the publication of trials' authorizations, progress and outcomes. Moreover, he emphasises the potential of Italy to maintain its leading role in international research endeavours, since Italian researchers and clinical facilities are among the world's best.​ ​ Ultimately, those promising perspectives represent an improved citizens' healthcare for the future, keeping in mind the commitment in using a comprehensible language for them during the care progresses.​ ​ Read the article below to learn more about these important steps towards the digitisation's evolution!​ . ​ #togethermovefirst #digitalmedicine #digitalhealth #clinicaltrials​ ​

13

🌟BMB srl for research against Fatal Familial Insomnia (FFI) 🌟 We are proud to support AFIFF | Association of Families Affected by Fatal Familial Insomnia. 🔍 FFI is a rare and devastating neurodegenerative disease that leads to progressive and unrelenting insomnia, causing severe mental and cognitive decline. Affecting the central nervous system, this illness heavily impacts the quality of life and, unfortunately, currently has no cure. At BMB srl, we believe our commitment goes beyond business: we support AFIFF because we want to do our part in promoting research and supporting affected families. 💙 Together, we can make a difference. Every action counts.💙 #BMBsrl #FFI #Solidarity #Donation #AFIFF #SocialResponsibility #Research #MentalHealth #FamilySupport #Community #FatalFamilialInsomnia #Awareness #SocialCommitment #Support #Neurodegeneration

8

📣 𝗦𝗔𝗩𝗘 𝗧𝗛𝗘 𝗗𝗔𝗧𝗘!   𝗩𝗔𝗫 𝗢𝗡 | 𝗩𝗮𝗰𝗰𝗶𝗻𝗲𝘀: 𝗣𝗿𝗲𝘀𝗲𝗻𝘁 𝗮𝗻𝗱 𝗙𝘂𝘁𝘂𝗿𝗲 𝗶𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗪𝗛𝗘𝗥𝗘: Milan, Italy 𝗪𝗛𝗘𝗡: October 1st, 2024 After decades of research and clinical trials, vaccines are beginning to impact patient outcomes. While the future is bright, we still have a long way to go.   An international meeting to share and discuss the latest findings and future perspectives on cancer vaccines. The objectives of the conference are to: - Present up-to-date data - Interpret clinical and scientific findings and predict potential impact - Recognize and characterize the hurdles that remain - Provide a vision for the future if hurdles are addressed 🔎 Stay tuned for the Scientific Program! ⏱ Registrations will open soon! Presidency: Paolo A. Ascierto, Bernard A. Fox PhD 👉 Info: [email protected] #Vivenko #VAXON #oncology #vaccines #clinicaltrials #savethedate

11

The CEO of NCNbio srl MariaLuisa Nolli was yesterday in Rome for the 3rd EU-Innovation Network multi-stakeholder Meeting "Translating Innovation into access for ATMPs" organized by European Medicines Agency, AIFA Agenzia Italiana del farmaco and Heads of Medicines Agencies and chaired by Falk Ehmann (EMA) and Paolo Foggi (AIFA, SAWP). It has been a valuable open forum to discuss the present framework and identify further actions that could facilitate patient access to safe and effective #advancedtherapies. The conclusions have been wrapped up in the Round Table "The most pressing needs – proposal for the next concrete actions", which underlined the need for properly funding those treatments, in the words of Gonzalo Calvo Rojas - Hospital Clínic de Barcelona. As a matter of fact, at the moment CAR-T therapies appear not to be sustainable for all the patients (Andrea Biondi - Università degli Studi di Milano-Bicocca). In order to extend the access to care, suggests Alessandro Aiuti - Università Vita-Salute San Raffaele, we should prevent disinvestment by companies, for example reducing the costs of regulatory compliance and ensuring the appropriate #intellectualproperty protection (Riccardo Ena - Assobiotec). All the stakeholders, highlights Pia Rivetti di Val Cervo, PhD - AIFA, must cooperate with a view to have a smoother process and a faster access to the treatments. #atmp

28

🌟New Insights into Complex Healthcare Needs for Heart Failure Patients 🌟 Our latest publication highlights the vital role of Care Manager in supporting elderly heart failure patients with multiple comorbidities. 🚀 Findings from our Italian clinical trials reveal key patient needs: - Education on managing heart failure and related conditions - Symptom monitoring and practical support for daily challenges - Coordinated communication with healthcare teams - Resources for self-management and mental health support 🔗 Read the full publication here: https://buff.ly/3Z0QO3c #HealthcareInnovation #HeartFailureCare #ESCAPEProject #CareManagement #PatientCenteredCare

7

1 commento

The Role of Germline BRCA Mutation in PARP Inhibitors-Related Hematologic Adverse Events - Carmine Valenza Eleonora Nicolò Dario Trapani Giuseppe Curigliano https://lnkd.in/ei6rJxBH #OncoDaily #Oncology #Cancer #Health #Medicine #Hematology

22

SPCC (Sharing Progress in Cancer Care) - Strategic Leading and Management in Cancer Care Continuum https://lnkd.in/dZVC8nR3 SDA Bocconi European Cancer Organisation European School of Oncology Organisation of European Cancer Institutes (OECI) #Cancer #CancerCare #Leadership #Health #HealthCare #Medicine #Oncology #OncoDaily

15

🌍 G7 Health Summit 2024: A Catalyst for Global Health Transformation! From October 9th to 11th, Ancona, Italy, hosted the G7 Health Summit, where health ministers from G7 nations and the EU Commission united with global representatives and organizations like the WHO and FAO. Together, they tackled urgent health challenges and envisioned the future of healthcare. 🤝 Key topics included universal health coverage, pandemic preparedness, and healthy ageing, with a strong emphasis on the “One Health” approach, highlighting the connections between human, animal, plant, and ecosystem health. A major focus was on artificial intelligence (AI) in healthcare, discussed in a dedicated policy brief. Leaders acknowledged AI’s potential to enhance diagnostics and access to care, while addressing concerns around bias, data privacy, and cybersecurity, underscoring the need for robust governance. ⚠️ The summit also spotlighted antimicrobial resistance (AMR), labelled a "true pandemic" by Italian Health Minister Orazio Schillaci, which claims over a million lives annually. Leaders emphasised the need for enhanced surveillance and responsible antimicrobial use to combat this escalating threat. 🚀 The G7 Health Summit marked a pivotal moment for global health policy. The challenge now is to turn these ambitious commitments into impactful actions for a healthier future. At RPP Group, we’re dedicated to championing these initiatives and driving meaningful change in healthcare policy. Together, let’s prioritise health on the global agenda! https://lnkd.in/eBuwcDeg #G7HealthSummit #GlobalHealth #PublicAffairs #ArtificialIntelligence #AntimicrobialResistance #OneHealth #HealthcareInnovation 

11

Dana-Farber’s Breast Oncology Center - The role of ADCs in the treatment of patients with Breast Cancer Brain Metastases Paolo Tarantino Sara Tolaney Sarah Sammons MD Dana-Farber Cancer Institute https://lnkd.in/eJ_Vr3vZ #ADCs #AntibodyDrugConjugates #BreastCancer #OncoDaily #Oncology  #BrainMetastases #Cancer #DanaFarber #BreastOncologyCenter  #Medicine #Health

48

📢 Fondazione Telethon was involved in the debate at the 12th European Conference on Rare Diseases and Orphan Products taking place in Brussels these last two days. 🔬 ECRD is the largest patient-led policy-shaping event for rare diseases in Europe and a unique opportunity to bring together all players in the field. And with the European elections approaching, this meeting was a platform to address priorities for the rare-disease community over the next five years.   🔬 Today Celeste Scotti MD, PhD, our Director of Research and Development, took part in a discussion about unequal access to innovative therapies for rare disease patients. Looking at the current scenario whereby research is developing more and more treatments but patient access is often hindered by sustainability issues, the debate focused on policies to solve this paradox.   Key aspects including high costs, payer reluctance, and disparities in health systems and legislations were discussed. Celeste Scotti illustrated the model currently being developed by Fondazione Telethon to provide access to advanced therapies in a non-profit framework thus bridging the gap for treatment when the industry-based model is inefficient at meeting patients’ needs, like in the case of ultra-rare diseases.  EURORDIS-Rare Diseases Europe

86

1 commento

While there are over 𝟭𝟬𝟬 𝗽𝗮𝘁𝗲𝗻𝘁𝘀 𝗼𝗻 𝗦𝗛𝗣𝟮 𝗮𝗹𝗹𝗼𝘀𝘁𝗲𝗿𝗶𝗰 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀, which underscores the target's importance and potential impact in oncology... there are very few 𝗯𝗿𝗮𝗶𝗻 𝗽𝗲𝗻𝗲𝘁𝗿𝗮𝗻𝘁 𝗦𝗛𝗣𝟮𝗶's in development, one of which was discovered by our scientists at IRBM. Our resident experts, Alessia Petrocchi and Alina Ciammaichella have analyzed all molecules in the public domain and they’ve just published a comprehensive review on the topic, with highlights including: ⌬ 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗖𝗼𝗺𝗽𝗼𝘂𝗻𝗱𝘀: Dive into the key structural elements of historical and/or leading SHP2 inhibitors like SHP099, TNO155, RMC-4630, and RLY(GDC)-1971. 👩🏻‍🔬 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀: 15 compounds have made it to clinical trials, with innovative combination therapies poised to break through resistance barriers and amplify treatment success. ⚗️ 𝗙𝘂𝘁𝘂𝗿𝗲 𝗗𝗶𝗿𝗲𝗰𝘁𝗶𝗼𝗻𝘀: The future of SHP2 inhibitors looks promising, especially in combination with other cutting-edge cancer treatments like MEK, BRAF, EGFR, RAS-G12C, and PDL-1 inhibitors. 𝗜𝗥𝗕𝗠'𝘀 𝗥𝗼𝗹𝗲: Our scientists are pushing the boundaries of 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗮𝗹 𝗰𝗵𝗲𝗺𝗶𝘀𝘁𝗿𝘆, contributing to the discovery and development of these groundbreaking SHP2 inhibitors, including the previously mentioned 𝗼𝗿𝗮𝗹𝗹𝘆 𝗯𝗶𝗼𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 & 𝗯𝗿𝗮𝗶𝗻 𝗽𝗲𝗻𝗲𝘁𝗿𝗮𝗻𝘁 𝗽𝗿𝗲-𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲 for treating challenging 𝗯𝗿𝗮𝗶𝗻 𝘁𝘂𝗺𝗼𝗿𝘀 and 𝗺𝗲𝘁𝗮𝘀𝘁𝗮𝘀𝗲𝘀. 👉 𝙎𝙬𝙞𝙥𝙚 𝙩𝙤 𝙩𝙝𝙚 𝙚𝙣𝙙 to read our lead author’s insights and to access the full article. PS -- follow IRBM to stay in the know about the latest in drug discovery and what's happening here at our unified research site. 🔔 #oncologyresearch #drugdiscovery #IRBM

63

1 commento

If you missed our Webinar about ‘Mastering Long-Term Clinical Data Retention: Strategies for Success’, or simply want to catch yourself up again with the insightful knowledge shared by our guest speakers, Simone Suriano, from Johnson & Johnson and Massimo Raineri from Arithmos, it is available to watch on demand! Watch on demand now!➡ https://zurl.co/T24d This webinar will will delve into effective methods, industry knowledge, and actionable approaches for achieving seamless digital archiving. An interesting opportunity to explore the topic and solve your doubts! #DigitalArchiving #ClinicalData #Webinar #lifescience #pharma #datamanagement #clinicaltrials

12

If you missed our Webinar about ‘Mastering Long-Term Clinical Data Retention: Strategies for Success’, or simply want to catch yourself up again with the insightful knowledge shared by our guest speakers, Simone Suriano, from Johnson & Johnson and Massimo Raineri from Arithmos, it is available to watch on demand! Watch on demand now!➡ https://zurl.co/UW0u This webinar will will delve into effective methods, industry knowledge, and actionable approaches for achieving seamless digital archiving. An interesting opportunity to explore the topic and solve your doubts! #DigitalArchiving #ClinicalData #Webinar #lifescience #pharma #datamanagement #clinicaltrials

3

If you missed our Webinar about ‘Mastering Long-Term Clinical Data Retention: Strategies for Success’, or simply want to catch yourself up again with the insightful knowledge shared by our guest speakers, Simone Suriano, from Johnson & Johnson and Massimo Raineri from Arithmos, it is available to watch on demand! Watch on demand now!➡ https://lnkd.in/eRXjz5jB This webinar will will delve into effective methods, industry knowledge, and actionable approaches for achieving seamless digital archiving. An interesting opportunity to explore the topic and solve your doubts! #DigitalArchiving #ClinicalData #Webinar #lifescience #pharma #datamanagement #clinicaltrials

4

If you missed our Webinar about ‘Mastering Long-Term Clinical Data Retention: Strategies for Success’, or simply want to catch yourself up again with the insightful knowledge shared by our guest speakers, Simone Suriano, from Johnson & Johnson and Massimo Raineri from Arithmos, it is available to watch on demand! Watch on demand now!➡ https://lnkd.in/eDJEXNxQ This webinar will will delve into effective methods, industry knowledge, and actionable approaches for achieving seamless digital archiving. An interesting opportunity to explore the topic and solve your doubts! #DigitalArchiving #ClinicalData #Webinar #lifescience #pharma #datamanagement #clinicaltrials

8

If you missed our Webinar about ‘Mastering Long-Term Clinical Data Retention: Strategies for Success’, or simply want to catch yourself up again with the insightful knowledge shared by our guest speakers, Simone Suriano, from Johnson & Johnson and Massimo Raineri from Arithmos, it is available to watch on demand! Watch on demand now!➡ https://zurl.co/dKTu This webinar will will delve into effective methods, industry knowledge, and actionable approaches for achieving seamless digital archiving. An interesting opportunity to explore the topic and solve your doubts! #DigitalArchiving #ClinicalData #Webinar #lifescience #pharma #datamanagement #clinicaltrials

3